HDL in sepsis - risk factor and therapeutic approach.
HDL in sepsis - risk factor and therapeutic approach.
复制标题
败血症中的HDL - 危险因素和治疗方法。
DOI：
10.3389/fphar.2015.00244
复制
发表时间：
2015
影响因子：
5.6
通讯作者：
Li XA
中科院分区：
文献类型：
--
作者：
Morin EE;Guo L;Schwendeman A;Li XA
高密度脂蛋白（HDL）是循环血液的重要组成部分，在调节血管内皮功能和免疫中起重要作用。临床资料表明，在脓毒症患者中，HDL水平下降40-70%，这与预后不良有关。用载脂蛋白A-I （ApoAI）缺失小鼠进行的实验研究表明，HDL缺乏小鼠易发生脓毒性死亡，在小鼠中过表达ApoAI以增加HDL水平可防止脓毒性死亡。这些临床和动物研究支持了我们的假设，即HDL水平的降低是脓毒症的危险因素，而提高循环HDL水平可能是脓毒症的有效治疗方法。在这篇综述中，我们讨论了HDL在脓毒症中的作用，并总结了利用合成HDL作为脓毒症的潜在治疗方法的努力。
High-density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40–70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAI) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAI in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.